木瓜直播

Breast cancer survival rate was 97% at 5 years

Responses in 60% of patients who had received a median of five prior lines of therapy

However, trial comparing robotic and open surgery was stopped early due to low enrollment

Study finds antiseptic agent non-inferior to daily, low-dose antibiotic prophylaxis

Presidential panel sets course to remove barriers, increase services, and improve uptake

Study finds positive lymph nodes not an indicator for chemotherapy

Italian data suggest a dose-response association

Large Swedish study showed the approach cut overdiagnosis, unnecessary biopsies

Almost 50% relative increase in ORR with pembrolizumab plus trastuzumab and chemotherapy

Benefit with China-developed tislelizumab in all patients and EU-North American subgroup

With cases increasing globally, researchers look to these commonly used drugs

Near 1-year improvement with radionuclide agent misses statistical significance

Four-month gain in OS with the addition of nab-paclitaxel to gemcitabine

ESMO Breast: Reassuring safety data for dual anti-HER2 therapy, antibody-drug conjugate